drugset / Trial / NCT01667029

Study of Sulfasalazine in Treating Painful Neuropathy

NCT01667029

Phase 2 Terminated 8 enrolled Massachusetts General Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The investigators hypothesize that sulfasalazine, an FDA-approved medication for rheumatoid arthritis and ulcerative colitis, may be beneficial in neuropathic pain conditions. In this study, the investigators will evaluate whether sulfasalazine improves pain due to painful peripheral neuropathy.

Timeline

Start
2013-05
Primary completion
2017-08-10
Completion
2017-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulfasalazine Small molecule 1 g Oral

Indications